Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD

Abstract

Roxadustat maintained Hb within 10 to 12 g/dl in NDD CKD patients and was noninferior to DA. The safety profiles observed in this study are consistent with previous studies performed in this patient population.